You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSecretin
Accession NumberDB00021  (BTD00039, BIOD00039)
TypeBiotech
GroupsApproved, Investigational
DescriptionThis drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine’s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.
Protein structureDb00021
Related Articles
Protein chemical formulaC130H219N43O42
Protein average weight3056.4 Da
Sequences
>DB00021 sequence
HSDGTFTSELSRLRDSARLQRLLQGLV
Download FASTA Format
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Secretin Inj 75unit/vialPowder, for solution75 unitIntravenousFerring Inc1990-12-311999-08-04Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SecreFloRepligen Corp
SecremaxRepligen Corp
Brand mixturesNot Available
SaltsNot Available
Categories
UNII88C55N56UU
CAS numberNot Available
Pharmacology
IndicationFor diagnosis of pancreatic exocrine dysfunction and gastrinoma
Structured Indications Not Available
PharmacodynamicsUsed in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.
Mechanism of actionSecretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone
TargetKindPharmacological actionActionsOrganismUniProt ID
Secretin receptorProteinyes
agonist
HumanP47872 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AclidiniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium.Approved
Anisotropine MethylbromideThe therapeutic efficacy of Secretin can be decreased when used in combination with Anisotropine Methylbromide.Approved
Atracurium besylateThe therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium besylate.Approved
AtropineThe therapeutic efficacy of Secretin can be decreased when used in combination with Atropine.Approved, Vet Approved
BenactyzineThe therapeutic efficacy of Secretin can be decreased when used in combination with Benactyzine.Withdrawn
BenzatropineThe therapeutic efficacy of Secretin can be decreased when used in combination with Benzatropine.Approved
BiperidenThe therapeutic efficacy of Secretin can be decreased when used in combination with Biperiden.Approved
ChlorphenoxamineThe therapeutic efficacy of Secretin can be decreased when used in combination with Chlorphenoxamine.Withdrawn
CyclopentolateThe therapeutic efficacy of Secretin can be decreased when used in combination with Cyclopentolate.Approved
DarifenacinThe therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin.Approved, Investigational
DesloratadineThe therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine.Approved, Investigational
DexetimideThe therapeutic efficacy of Secretin can be decreased when used in combination with Dexetimide.Withdrawn
DicyclomineThe therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.Approved
EthopropazineThe therapeutic efficacy of Secretin can be decreased when used in combination with Ethopropazine.Approved
FesoterodineThe therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.Approved
Gallamine TriethiodideThe therapeutic efficacy of Secretin can be decreased when used in combination with Gallamine Triethiodide.Approved
GlycopyrroniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Glycopyrronium.Approved, Investigational, Vet Approved
HexamethoniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Hexamethonium.Experimental
HomatropineThe therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine.Approved
HyoscyamineThe therapeutic efficacy of Secretin can be decreased when used in combination with Hyoscyamine.Approved
Ipratropium bromideThe therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.Approved
MecamylamineThe therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.Approved
MethanthelineThe therapeutic efficacy of Secretin can be decreased when used in combination with Methantheline.Approved
MetixeneThe therapeutic efficacy of Secretin can be decreased when used in combination with Metixene.Approved
N-butylscopolammonium bromideThe therapeutic efficacy of Secretin can be decreased when used in combination with N-butylscopolammonium bromide.Vet Approved
NVA237The therapeutic efficacy of Secretin can be decreased when used in combination with NVA237.Investigational
OrphenadrineThe therapeutic efficacy of Secretin can be decreased when used in combination with Orphenadrine.Approved
OxybutyninThe therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Oxyphenonium.Approved
PancuroniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Pancuronium.Approved
PentoliniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Pentolinium.Approved
PipecuroniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Pipecuronium.Approved
PirenzepineThe therapeutic efficacy of Secretin can be decreased when used in combination with Pirenzepine.Approved
ProcyclidineThe therapeutic efficacy of Secretin can be decreased when used in combination with Procyclidine.Approved
PropanthelineThe therapeutic efficacy of Secretin can be decreased when used in combination with Propantheline.Approved
PropiverineThe therapeutic efficacy of Secretin can be decreased when used in combination with Propiverine.Investigational
QuinidineThe therapeutic efficacy of Secretin can be decreased when used in combination with Quinidine.Approved
ScopolamineThe therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine.Approved
Scopolamine butylbromideThe therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine butylbromide.Approved
SolifenacinThe therapeutic efficacy of Secretin can be decreased when used in combination with Solifenacin.Approved
TiotropiumThe therapeutic efficacy of Secretin can be decreased when used in combination with Tiotropium.Approved
TolterodineThe therapeutic efficacy of Secretin can be decreased when used in combination with Tolterodine.Approved, Investigational
TrihexyphenidylThe therapeutic efficacy of Secretin can be decreased when used in combination with Trihexyphenidyl.Approved
TrimethaphanThe therapeutic efficacy of Secretin can be decreased when used in combination with Trimethaphan.Approved
TropicamideThe therapeutic efficacy of Secretin can be decreased when used in combination with Tropicamide.Approved
TrospiumThe therapeutic efficacy of Secretin can be decreased when used in combination with Trospium.Approved
TubocurarineThe therapeutic efficacy of Secretin can be decreased when used in combination with Tubocurarine.Approved
UmeclidiniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Umeclidinium.Approved
VecuroniumThe therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.Approved
Food InteractionsNot Available
References
Synthesis Reference

Martin Bickel, Rolf Geiger, Richard Leeb, Walter Petri, “Secretin preparations with intensified and protracted action, process for their manufacture, their use as well as dihydroxybenzoyl-L-tyrosine.” U.S. Patent US4302448, issued August, 1964.

US4302448
General ReferencesNot Available
External Links
ATC CodesV04CK01
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Pharmacoeconomics
Manufacturers
  • Ferring pharmaceuticals inc
  • Chirhoclin inc
Packagers
  • Professional Co.
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous75 unit
Prices
Unit descriptionCostUnit
Secretin-mannitol powder1.43USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
hydrophobicity-0.463Not Available
isoelectric point9.45Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Secretin receptor activity
Specific Function:
This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
SCTR
Uniprot ID:
P47872
Molecular Weight:
50206.135 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23